In patients with type 2 diabetes and high cardiovascular risk, once-weekly semaglutide significantly reduced the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) compared to placebo, though it was associated with a higher risk of diabetic retinopathy complications.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
In patients with type 2 diabetes, once-weekly semaglutide significantly improved glycaemic control (HbA1c reduction) and reduced body weight in a dose-dependent manner compared to placebo, with efficacy at the highest doses surpassing that of daily liraglutide, though it was associated with gastrointestinal side effects.
In patients with type 2 diabetes on diet and exercise or metformin, oral semaglutide significantly improved glycemic control (HbA1c reduction) and weight loss in a dose-dependent manner compared to placebo, with similar efficacy to subcutaneous semaglutide, though it was associated with higher rates of gastrointestinal side effects.